The funding from Venture Kick will enable Recolony to advance its small molecule program towards the pre-clinical phase to provide cancer patients with a novel, more effective, safer therapeutic solution. In 2025, the biotech startup plans to perform the first-in-human clinical trials with CRC patients at the University Hospital of Zurich. The additional capital comes after the startup received Innobooster financial support.